Search Within

Matthew David Hellmann

  1. "2020"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (23)
  3. Editorial (2)
  4. Review (2)
  5. Research Letter (1)
Groups
  1. Department of Medicine (55)
  2. Solid Tumor Oncology Division (55)
  3. Thoracic Oncology (55)
  4. GSK Faculty (20)
  5. Weinberg Fellows (20)
  6. Melanoma and Immunotherapeutics Service (14)

More Groups

People
  1. Hira Rizvi (20)
  2. Charles Rudin (13)
  3. Jamie Chaft (11)
  4. Andrew Plodkowski (10)
  5. Jia Luo (10)
  6. Mark Kris (9)

More People

Years
  1. 2020 (55)
Publications
  1. Journal of Clinical Oncology (12)
  2. Annals of Oncology (7)
  3. Cancer Research (6)
  4. Clinical Cancer Research (4)
  5. Cancer Discovery (3)
  6. Cell (3)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (12)
  3. Oxford University Press (7)
  4. Elsevier Inc. (6)
  5. Cell Press (5)
  6. Biomed Central Ltd (3)

More Publishers

Results (55)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Effect of STK11 mutations on efficacy of PD-1 inhibition in non-small cell lung cancer (NSCLC) and dependence on KRAS mutation status
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Lin, J. J.; Vokes, N.; Hoojghan, A. V.; Li, Y. Y.; Cherniack, A. D.; Recondo, G.; Lamberti, G.; Venkatraman, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Locoregional control, failure patterns and clinical outcomes in patients with stage III non-small cell lung cancers treated with chemoradiation and durvalumab
    Meeting Abstract

    Offin, M.; Shaverdian, N.; Rimner, A.; Lobaugh, S.; Shepherd, A.; Simone, C. B.; Gelblum, D. Y.; Wu, A. J. C.; Lee, N. Y.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Strategies to improve the sensitivity and ranking ability of neoantigen prediction methods: Report on the results of the Tumor nEoantigen SeLection Alliance (TESLA)
    Meeting Abstract

    Wells, D. K.; Dang, K.; Hubbard-Lucey, V. M.; Sheehan, K. C.; Lamb, A.; Ward, J. P.; Sidney, J.; Blazquez, A. B.; Rech, A. J.; Zaretsky, J.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Alignment of TMB measured on clinical samples: Phase IIB of the Friends of Cancer Research TMB Harmonization Project
    Meeting Abstract

    Merino, D. M.; Yee, L. M.; McShane, L. M.; Williams, P. M.; Vilimas, T.; Patidar, R.; Barrett, J. C.; Chen, S. J.; Cheng, J. H.; Conroy, J. M.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors
    Meeting Abstract

    Lopez, J. S.; Camidge, R.; Iafolla, M.; Rottey, S.; Schuler, M.; Hellmann, M.; Balmanoukian, A.; Dirix, L.; Gordon, M.; Sullivan, R.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Integrative genomic analysis of checkpoint blockade in lung cancer: A multi-institution SU2C collaborative
    Meeting Abstract

    Arniella, M.; Ravi, A.; Stewart, C.; Freeman, S.; Awad, M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J.; Gibbons, D.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Tim-4(+) resident macrophages impair anti-tumor immunity in the serous body cavities by sequestering viable and cytotoxic CD8(+) T cells expressing high levels of phosphatidylserine
    Meeting Abstract

    Chow, A.; Schad, S.; Green, M.; Hellmann, M.; Ceglia, N.; Allaj, V.; Zago, G.; Shah, N.; Sharma, S.; Mattar, M.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • The genomic landscape of SMARCA4 alterations and associations with outcomes in patients with lung cancer
    Journal Article

    Schoenfeld, A.; Bandlamudi, C.; Lavery, J. A.; Montecalvo, J.; Namakydoust, A.; Rizvi, H.; Egger, J.; Concepcion, C. P.; Paul, S.; Arcila, M. E.; more...
    Clinical Cancer Research (2020)

    Fulltext@MSK | Save
  • Survival of responders to nivolumab (NIVO) + ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Meeting Abstract

    Brahmer, J. R.; Ciuleanu, T. E.; Schenker, M.; Audigier-Valette, C.; Zurawski, B.; Linardou, H.; Kim, S. W.; Otterson, G. A.; Salman, P.; De La Mora Jimenez, E.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade
    Journal Article

    Zhang, Q.; Luo, J.; Wu, S.; Si, H.; Gao, C.; Xu, W.; Abdullah, S. E.; Higgs, B. W.; Dennis, P. A.; van der Heijden, M. S.; more...
    Cancer Discovery (2020)

    Fulltext@MSK | Save